Tissue Regenix Group PLC dCELL(R) presented at prestigious EACTS congress
October 20 2014 - 5:19AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
20 October 2014
Tissue Regenix Group Plc
Tissue Regenix's dCELL(R) aortic heart valve technology
presented at prestigious EACTS congress
YORK, 20(th) October 2014 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the regenerative medical devices
company, has had a patient study into the efficacy of its dCELL(R)
aortic heart valves showcased at the 28th Annual Meeting of the
European Association of Cardio Thoracic Surgery (EACTS) in
Milan.
Tissue Regenix's long-term clinical collaborator, Professor
Francisco da Costa, presented an update based on nearly nine years
of research data.
Professor da Costa has pioneered the use of decellularised
aortic heart valve implants in human patients and the findings
presented at the EACTS congress suggest that decellularised human
aortic heart valves, developed using Tissue Regenix's patented
dCELL(R) technology, could provide a more effective treatment than
cryopreserved aortic valve substitutes.
Professor da Costa's study is the largest and longest-running
study conducted globally into patient outcomes based on treatment
with decellularised aortic heart valves, with aortic implants
remaining the most commonly undertaken heart valve operation.
Professor Francisco da Costa, an internationally renowned
cardiac surgeon from Pontifical University of Parana, Brazil, has
amassed the data in his report from 86 patient implants undertaken
at his institution between 2005 and 2014 with follow-up review and
patient monitoring up to the present date.
The study is also notable because the patients treated are in
younger and harder to treat age groups, with the mean age of the
cohort averaging 44 years-old, with patients ranging in age from
children to older adults. All patients in the study are considered
high risk due to conditions including recurrent endocarditis and
third or fourth redo operations.
Key findings of the study include:
-- The gradients, a first indicator of dysfunction, stayed very
low and stable over the study period
-- 94% of patients were free from more than moderate
regurgitation (where blood leaks back through the aortic valve
because the valve does not close properly. With each heartbeat,
more blood than usual enters the heart and so it needs to work
harder sometimes leading to failure)
-- The patient's diseased heart valve led to a pathological
increase of the left heart chamber. After treatment this chamber
remodelled towards normal
-- Freedom from reoperation in this high risk group was 94% after 7 years
-- Scans showed essential absence of calcification, a particular problem in younger patients
Professor Francisco da Costa stated: "We are very happy with the
results in this young, high risk patient population, the incidence
of reoperation is very low and the results are promising. The
evaluation continues and we hope to see on-going progress based on
this dCELL(R) regenerative medicine treatment."
Tissue Regenix's dCELL(R) technology decellularises human donor
heart valves, producing an inert scaffold which is implanted into
the patient to act as a mechanical scaffold that is partially
populated by the patient's own cells. The dCELL(R) heart valve
regenerates to become part of the patient's body, providing a more
durable repair with significantly reduced risk of rejection and
degeneration.
The dCELL(R) heart valve technology is being developed to target
a global tissue heart valve market which is worth in excess of
$1.0bn a year. Aortic valve replacements represent the majority of
heart valve replacement procedures currently undertaken.
- ENDS -
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Andrew Adie
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGGMUUUPCUBU
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024